Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNC-102
- Development stage
- Phase 2
- Lead developer
- Synchroneuron
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral
01
Overview
SNC-102 is a novel, sustained-release oral formulation of acamprosate calcium developed by Synchroneuron. Acamprosate calcium is an FDA-approved drug for alcohol dependence, but SNC-102 was designed to improve its pharmacokinetic properties for new indications. The primary mechanism involves modulation of excitatory and inhibitory neurotransmission in the central nervous system, aiming to address movement disorders and neuropsychiatric conditions such as tardive dyskinesia (TD), Tourette syndrome, and combat-related posttraumatic stress disorder (cPTSD). Clinical trials have evaluated its efficacy in these areas; however, several studies were withdrawn or discontinued before completion[2][4][5][7][9].
- Other names
- acamprosate calcium sustained release tablet
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on SNC-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNC-102.